



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Erythroid/myeloid progenitors and hematopoietic stem cells originate from distinct populations of endothelial cells

Citation for published version:

Chen, MJ, Li, Y, De Obaldia, ME, Yang, Q, Yzaguirre, AD, Yamada-Inagawa, T, Vink, CS, Bhandoola, A, Dzierzak, E & Speck, NA 2011, 'Erythroid/myeloid progenitors and hematopoietic stem cells originate from distinct populations of endothelial cells', *Cell Stem Cell*, vol. 9, no. 6, pp. 541-52.
<https://doi.org/10.1016/j.stem.2011.10.003>

Digital Object Identifier (DOI):

[10.1016/j.stem.2011.10.003](https://doi.org/10.1016/j.stem.2011.10.003)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Peer reviewed version

Published In:

Cell Stem Cell

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.





Published in final edited form as:

Cell Stem Cell. 2011 December 2; 9(6): 541–552. doi:10.1016/j.stem.2011.10.003.

Erythroid/myeloid progenitors and hematopoietic stem cells originate from distinct populations of endothelial cells

Michael J. Chen¹, Yan Li¹, Maria Elena De Obaldia², Qi Yang², Amanda D. Yzaguirre¹, Tomoko Yamada-Inagawa³, Chris S. Vink³, Avinash Bhandoola², Elaine Dzierzak³, and Nancy A. Speck^{1,4}

¹Abramson Family Cancer Research Institute and Department of Cell and Developmental Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104

²Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104 ³Erasmus Stem Cell Institute, Department of Cell Biology, Erasmus MC, Rotterdam, The Netherlands

Summary

Hematopoietic stem cells (HSC) and an earlier wave of definitive erythroid/myeloid progenitors (EMPs) differentiate from hemogenic endothelial cells in the conceptus. EMPs can be generated *in vitro* from embryonic or induced pluripotent stem cells, but efforts to produce HSCs have largely failed. The formation of both EMPs and HSCs requires the transcription factor Runx1 and its non-DNA binding partner core binding factor β (CBF β). Here we show that the requirements for CBF β in EMP and HSC formation in the conceptus are temporally and spatially distinct. Pan-endothelial expression of CBF β in *Tek*-expressing cells was sufficient for EMP formation, but was not adequate for HSC formation. Expression of CBF β in *Ly6a*-expressing cells, on the other hand, was sufficient for HSC but not EMP formation. The data indicate that EMPs and HSCs differentiate from distinct populations of hemogenic endothelial cells, with *Ly6a* expression specifically marking the HSC-generating hemogenic endothelium.

Introduction

Hematopoietic stem cells (HSCs), which reside in the bone marrow of adult mammals, differentiate from a small population of endothelial cells in the conceptus referred to as “hemogenic endothelium” (Bertrand et al.; Boisset et al., 2010; Chen et al., 2009; Jaffredo et al., 2005; Kissa et al., 2008; Zovein et al., 2008). Before HSCs appear, committed erythroid/myeloid progenitors (EMPs) emerge in the yolk sac, also from hemogenic endothelium. HSCs capable of repopulating adult mice are first detected at 10.5 days post coitus (dpc; 35 somite pair stage, or 35s) in the dorsal aorta, vitelline and umbilical arteries, and at 11.0–11.5 dpc in the fetal liver, yolk sac, and placenta (de Bruijn et al., 2000; Gekas et al., 2005; Medvinsky et al., 1996; Müller et al., 1994; Ottersbach and Dzierzak, 2005). Hemogenic endothelium is located in all sites of EMP and HSC emergence including the ventral aspect of the dorsal aorta, vitelline and umbilical arteries, yolk sac, and placenta. The process by

© 2011 Il Press. All rights reserved.

⁴Corresponding author. Phone: 215-746-5013, Fax: 215-573-2486, nancyas@exchange.upenn.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

which blood forms from hemogenic endothelium has been most well studied in the dorsal aorta and in ES cell cultures, and involves an endothelial to hematopoietic cell transition during which individual cells round up and detach from the endothelial layer (Bertrand et al.; Boisset et al., 2010; Kissa et al., 2008). This rounding up (budding) process can be towards the lumen of an artery (prominent in mammals and birds) (Jaffredo et al., 2005), where many newly formed hematopoietic cells collect in clusters that are presumably released into the circulation. Alternatively, the budding can occur in the opposite direction, into the subaortic mesenchyme, after which single hematopoietic cells enter the circulation through the axial vein by intravasation (zebrafish) (Bertrand et al.; Kissa et al., 2008).

Hemogenic endothelium is distinguished from all other endothelial cells by the presence of a transcription factor called Runx1 (North et al., 1999). Runx1 is expressed in hemogenic endothelial cells in early somite pair stage conceptuses prior to the formation of clusters, in the clusters themselves, and in all functional EMPs and HSCs (North et al., 2002; North et al., 1999). Fetuses lacking Runx1 have no EMPs, HSCs, or intra-arterial clusters (Cai et al., 2000; North et al., 2002; North et al., 1999; Okuda et al., 1996; Wang et al., 1996a). In zebrafish Runx1 morphants, most aortic endothelial cells did not attempt the endothelial to hematopoietic cell transition, and those that did self-destructed by what appeared to be an apoptotic-like process (Kissa and Herbomel, 2010).

We showed that deletion of a conditional *Runx1* allele in endothelial cells with Cre recombinase driven from *Cdh5* (encoding vascular endothelial cadherin) or *Tek* (encoding the angiopoietin receptor Tie2) regulatory sequences blocked EMP, HSC, and intra-arterial cluster formation, indicating that Runx1 is required in the hemogenic endothelium for the endothelial to hematopoietic cell transition (Chen et al., 2009; Li et al., 2006). A complementary study (Liakhovitskaia et al., 2009) demonstrated that restoring Runx1 function in endothelial cells in Runx1 deficient embryos rescued both EMP and HSC formation. The latter experiment involved reactivating an inactive *Runx1* allele with *Tek-Cre*, allowing Runx1 to be appropriately expressed from its endogenous locus in *Tek*⁺ hemogenic endothelial cells, and all of their progeny throughout the remainder of hematopoietic development.

Runx1 function during hematopoiesis requires the activity of a non-DNA binding subunit, core binding factor β (CBF β), which allosterically regulates DNA binding by Runx1 (Sasaki et al., 1996; Wang et al., 1996b; Yan et al., 2004). Fetuses lacking CBF β had dramatically impaired hematopoiesis, although some residual EMPs remained (Wang et al., 1996b). Fetuses with only 15% of wildtype CBF β levels had functional EMPs and HSCs (Talebian et al., 2007), thus very low levels of CBF β are needed to support EMP and HSC formation. We previously showed that restoring CBF β expression in *Tek*⁺ cells would rescue EMP formation in the fetus (Miller et al., 2002). Our rescue strategy was different from that employed by Liakhovitskaia *et al.* (Liakhovitskaia et al., 2009), in that we expressed CBF β (fused to the green fluorescent protein, GFP/CBF β) as a transgene from *Tek* regulatory sequences in CBF β deficient fetuses (Miller et al., 2002). Although GFP/CBF β was detected in endothelial cells, its level in hematopoietic cells, including Sca1⁺ or c-Kit⁺ fetal liver cells, was low (Miller et al., 2002). Fetal liver EMPs were rescued by the *Tek-GFP/Cbfb* transgene, but GFP/CBF β was not expressed at later stages of blood cell differentiation, and consequently the terminal differentiation of all hematopoietic cells, with the exception of erythrocytes, was impaired.

Another marker of endothelial cells in hematopoietic sites is the HSC cell surface protein Sca-1, which is encoded by the *Ly6a* gene (de Bruijn et al., 2002; Ottersbach and Dzierzak, 2005). Surface Sca-1 is found on only 50% of AGM HSCs (de Bruijn et al., 2002; North et al., 2002). However, expression of green fetal fluorescent protein (GFP) from the *Ly6a*

regulatory sequences marked all functional HSCs in the dorsal aorta, fetal liver, and placenta (de Bruijn et al., 2002; Ottersbach and Dzierzak, 2005). GFP⁺ cells were found amongst the endothelial cells of the dorsal aorta, vitelline and umbilical arteries, and placenta, but not all endothelial cells in these sites were GFP⁺. A recently published live imaging study that utilized the *Ly6a-GFP* transgene tracked the budding of GFP⁺ hematopoietic cells into the lumen of the dorsal aorta in slice cultures from 10.5 dpc fetuses (Boisset et al., 2010).

Here we show that a GFP/CBF β fusion protein expressed from the *Tek* regulatory sequences in CBF β deficient mice is sufficient to restore EMPs formation, but insufficient for HSC formation. Conversely, expressing GFP/CBF β from *Ly6a* regulatory sequences will rescue HSC formation, but not EMP formation. These data indicate that EMP and HSC formation can be uncoupled, and that *Ly6a* expression specifically marks a subset of hemogenic endothelial cells that are destined to produce HSCs.

Results

Expression of GFP/CBF β from the *Tek* regulatory sequences cells fails to rescue HSCs in *Cbfb*^{-/-} fetuses

We previously showed that a GFP/CBF β fusion protein, when expressed from a *Tek*-driven transgene, could rescue EMPs in the fetal liver of 12.5 dpc *Cbfb*^{-/-} fetuses (Miller et al., 2002). The number of EMPs was lower than in wild type fetuses, but was sufficient for *Cbfb*^{-/-}; *Tek-GFP/Cbfb* conceptuses to complete gestation (lethality was at postnatal day 1). *Cbfb*^{-/-} fetuses, on the other hand, died at midgestation with almost no EMPs (Miller et al., 2002; Wang et al., 1996b). We also showed that 17.5 dpc *Cbfb*^{-/-}; *Tek-GFP/Cbfb* fetuses contained both B and T lymphocytes, but in reduced numbers (Miller et al., 2002). We assessed the B and T lymphoid potential of 14.5 dpc *Cbfb*^{-/-}; *Tek-GFP/Cbfb* fetuses by isolating fetal liver lymphoid progenitors (Lin⁻ c-Kit⁺Flt3⁺) and co-culturing them with either OP9 stromal cells or Notch-ligand expressing OP9-DL4 stromal cells. *Cbfb*^{-/-}; *Tek-GFP/Cbfb* progenitors yielded small numbers of CD19⁺B220⁺ B cells in OP9 cultures, and Thy1⁺CD25⁺ T cells in OP9-DL4 cultures (Figure 1A). Limit dilution analysis determined that *Cbfb*^{-/-}; *Tek-GFP/Cbfb* fetal livers contained approximately 30 fold fewer B cell and 15 fold fewer T cell progenitors within the Lin⁻ c-Kit⁺Flt3⁺ population as compared to *Cbfb*^{+/+}; *Tek-GFP/Cbfb* (heretofore referred to as *Tek-GFP/Cbfb*) fetal livers (Figure 1B). Methylcellulose colony assays using unfractionated fetal liver cells similarly showed that *Cbfb*^{-/-}; *Tek-GFP/Cbfb* fetuses contained 11 fold fewer B progenitors than *Tek-GFP/Cbfb* fetuses (not shown). We transplanted 14.5 dpc fetal liver cells from *Cbfb*^{-/-}; *Tek-GFP/Cbfb* conceptuses into irradiated adult mice to assess HSCs and observed no donor contribution to the peripheral blood or bone marrow (Figure 1C). Thus fetal liver lymphoid progenitors and HSCs are poorly rescued by the *Tek-GFP/Cbfb* transgene.

Examination of the fetal liver revealed that there were lower numbers of cells overall, and even fewer Lin⁻ Sca1⁺ c-Kit⁺ (LSK) cells (Figure 1D). We previously showed by Western blot that the amount of GFP/CBF β fusion protein produced from the *Tek-GFP/Cbfb* transgene in embryonic skin was equivalent to that of endogenous CBF β , but was undetectable in CD45⁺ or c-Kit⁺ fetal liver cells (Miller et al., 2002). We extended those findings by examining GFP/CBF β levels in phenotypic HSCs and LT-HSCs by FACS. Fewer than 10% of phenotypic HSCs (LS Mac1⁺) and LT-HSCs (CD48⁻ CD150⁺ LS Mac1⁺) in the liver of *Tek-GFP/Cbfb* fetuses were GFP/CBF β ⁺ (Figure 1E). Thus, GFP/CBF β expression from the *Tek-GFP/Cbfb* transgene is not sustained in the majority of newly formed HSCs, which, as discussed later, may contribute to its failure to rescue HSC formation in *Cbfb*^{-/-} fetuses.

Expression of GFP/CBF β from the Ly6a regulatory sequences fails to rescue EMPs

We next tried to rescue EMP and HSC formation in *Cbfb*^{-/-} fetuses using a *Ly6a*-driven transgene. Three *Ly6a-GFP/Cbfb* founders were generated, all of which produced GFP/CBF β at levels similar to that of endogenous CBF β in unfractionated adult bone marrow cells (Figure 2A). Essentially 100% of adult bone marrow LSK and CD48⁻ CD150⁺ LSK cells in *Ly6a-GFP/Cbfb* mice were GFP/CBF β ⁺, although the mean fluorescence intensity differed in independent founder lines (line A>B>C) (Figure 2B). Expression from the *Ly6a-GFP/Cbfb* transgene at 11.5 dpc mirrored that described for *Ly6a-GFP* (de Bruijn et al., 2002; Ottersbach and Dzierzak, 2005). GFP/CBF β ⁺ cells were present in the placental and umbilical vasculature, vitelline artery, and AGM region (including the mesonephric tubules and Wolffian/Mullerian ducts) (Figure 2C). Fetal liver CD48⁻ CD150⁺ LSK cells were ~80% GFP/CBF β ⁺ in the strongest-expressing *Ly6a-GFP/Cbfb* line (Figure 2D).

The three independent *Ly6a-GFP/Cbfb* transgenes were crossed onto the *Cbfb*^{-/-} background. Surprisingly, *Cbfb*^{-/-};*Ly6a-GFP/Cbfb* conceptuses died in utero at the same time as *Cbfb*^{-/-} conceptuses (Figure S1). *Cbfb*^{-/-};*Ly6a-GFP/Cbfb* fetal livers were pale, suggesting that colonization by yolk sac EMPs had not occurred. Hematopoietic assays were performed to examine EMPs in *Cbfb*^{-/-};*Tek-GFP/Cbfb* versus *Cbfb*^{-/-};*Ly6a-GFP/Cbfb* versus *Cbfb*^{-/-};*Tek-GFP/Cbfb*;*Ly6a-GFP/Cbfb* conceptuses (Figure 3). Two-way comparisons using Student's t-test revealed significantly higher numbers of EMPs in *Cbfb*^{-/-};*Tek-GFP/Cbfb* versus *Cbfb*^{-/-} conceptuses (fetal liver and yolk sac), and in *Cbfb*^{-/-};*Tek-GFP/Cbfb* versus *Cbfb*^{-/-};*Ly6a-GFP/Cbfb* conceptuses (fetal liver and placenta) at 11.5 dpc (Figure 3). Although the number of EMPs in *Cbfb*^{-/-};*Tek-GFP/Cbfb* fetal livers was initially low, it increased considerably over the next few days, and by 14.5 dpc EMPs were only 33% fewer in number than in *Tek-GFP/Cbfb* conceptuses (Figure 3). *Cbfb*^{-/-} fetuses carrying both the *Tek-GFP/Cbfb* and *Ly6a-GFP/Cbfb* transgenes had significantly higher numbers of EMPs in all tissues at 11.5 dpc (Figure 3), indicating that the two transgenes complemented each other. In summary, the *Tek-GFP/Cbfb* transgene rescues EMPs and fetal viability significantly better than the *Ly6a-GFP/Cbfb* transgene. We conclude that the *Ly6a-GFP/Cbfb* transgene is not expressed at the correct time, or in the correct cells to adequately restore EMP formation and rescue the viability of *Cbfb*^{-/-} fetuses.

Expression of GFP/CBF β from the Ly6a regulatory sequences rescues HSCs

Since most *Cbfb*^{-/-};*Ly6a-GFP/Cbfb* fetuses died by 13.5 dpc, we assayed hematopoietic tissues at 11.5 dpc for the presence of HSCs. Quite surprisingly, the *Ly6a-GFP/Cbfb* transgene restored HSC formation in all hematopoietic tissues except for the AGM region, vitelline and umbilical arteries (A+U+V) (Figure 4A). High-level reconstitution by *Cbfb*^{-/-};*Ly6a-GFP/Cbfb* HSCs was observed in multiple recipients (6 out of 17), with contribution to both lymphoid and myeloid lineage cells (Figure 4B). *Cbfb*^{-/-} fetuses expressing both the *Tek-GFP/Cbfb* and *Ly6a-GFP/Cbfb* transgenes had HSCs in all hematopoietic sites including the A+U+V (Figure 4A), thus the two transgenes complemented each other in HSC formation. We observed reconstitution of only one recipient by *Cbfb*^{-/-};*Tek-GFP/Cbfb* HSCs that had received 0.9 embryo equivalents of placental cells. These results confirm previous data showing that HSCs are associated with endothelium marked by *Ly6a* transgene expression (de Bruijn et al., 2002; Ottersbach and Dzierzak, 2005), and further show that CBF β function in *Ly6a*-expressing cells is sufficient for HSC, but not for EMP formation.

Comparison of Tek-GFP/Cbfb and Ly6a-GFP/Cbfb expression

Since the *Tek*-driven transgene selectively rescued EMP formation, and the *Ly6a*-driven transgene restored only HSC formation, comparison of their expression patterns during

embryonic development should reveal when and in what cells CBF β is required. We first considered why the *Ly6a-GFP/Cbfb* transgene failed to rescue EMP formation. EMPs are detected in the yolk sac beginning at 8.25 dpc (2–6s) (Palis et al., 1999) as clusters of CD41^{bright} cells at the border between the yolk sac blood islands and the capillary bed leading to the embryo proper (Ferkowicz et al., 2003). No GFP/CBF β ⁺ cells were found anywhere in *Ly6a-GFP/Cbfb* conceptuses at this time or in slightly older 10–11s conceptuses (Figure 5B). In contrast, the *Tek-GFP/Cbfb* transgene, which rescued EMP formation, was highly expressed in endothelial cells throughout 6–7s conceptuses, in the yolk sac vascular plexus, dorsal aortae, heart (endocardial tube), allantois, and placenta (Figure 5A). Therefore the *Tek-GFP/Cbfb* transgene was expressed in endothelial cells at the time of EMP emergence in the yolk sac, but the *Ly6a-GFP/Cbfb* transgene was not.

The fact that the *Ly6a-GFP/Cbfb* transgene rescued HSC formation means that the onset of its expression could define the earliest time point at which CBF β is required to specify HSCs. Initiation of *Ly6a-GFP/Cbfb* transgene expression was found in a subset of endothelial cells between 11s and 16s (~9 dpc) (Figure 5D and Movie S1). These included endothelial cells in the dorsal aorta, the vitelline vasculature, placenta, and the yolk sac vascular plexus primarily (although not exclusively) at the caudal end of the conceptus. A half day later (24s, 9.5 dpc), expression of *Ly6a-GFP/Cbfb* in the yolk sac is confined to the major vitelline vessels (Figure S2 and Movie S2). The appearance of *Ly6a-GFP/Cbfb* expressing endothelial cells precedes the presence of both yolk sac HSCs capable of repopulating busulfan-conditioned neonatal recipients (13–20s) (Yoder et al., 1997) and AGM HSCs that can repopulate adult irradiated recipients (>34s, 10.5 dpc) (Medvinsky and Dzierzak, 1996; Müller et al., 1994). Thus, CBF β is not necessary for HSC formation until, at the very earliest, the 11–16s stage. Further, the inability of the *Ly6a-GFP/Cbfb* transgene to rescue EMP formation indicates that CBF β is required before the 16s stage for EMP formation, and/or that EMPs develop from *Ly6a* negative endothelial cells.

Transgene expression was also examined at 10.5 dpc, when adult repopulating HSCs appear. *Ly6a-GFP/Cbfb* expression was intense in a subset of endothelial cells located in the regions of HSC emergence, including the dorsal aorta, umbilical and vitelline vasculature (Figure 6B and Movie S3). GFP/CBF β ⁺ cells in the yolk sac were mostly confined to the larger vitelline vessels, as reported previously (Figure 6D) (de Bruijn et al., 2002). In contrast to the *Ly6a*-driven transgene, which marks a relatively restricted population of endothelial cells that include a subset of hemogenic endothelial cells, the *Tek-GFP/Cbfb* transgene was expressed throughout the vasculature of the 10.5 dpc conceptus, although not uniformly in all endothelial cells (Figure 6A,E). *Tek-GFP/Cbfb* was also expressed the yolk sac at 10.5 dpc in the vascular plexus as well as in the larger vitelline vessels (Figure 6C). FACS analysis of A+U+V of 11.5 dpc *Tek-GFP/Cbfb* and *Ly6a-GFP/Cbfb* conceptuses indicated that 18.2% and 20.2%, respectively, of CD144⁺ CD45⁻ endothelial cells were GFP/CBF β ⁺ (Figure S3, panel C). Fetuses expressing both transgenes had a significantly higher percentage of endothelial cells that were GFP/CBF β ⁺ (33.5%) suggesting that the two transgenes were expressed in partially non-overlapping endothelial cell populations. Thus, the differences in the percentage of endothelial cells expressing *Tek-GFP/Cbfb* versus *Ly6a-GFP/Cbfb* do not underlie the distinct abilities of these two transgenes to rescue EMPs and HSCs. The failure of the *Tek-GFP/Cbfb* transgene to rescue HSCs must either be due to suboptimal expression in endothelial cells that give rise to HSCs, or premature extinction of its expression in HSCs.

We examined whether other HSC/endothelial markers could be used as surrogates for *Ly6a*-driven transgenes. Endothelial specific adhesion molecule (ESAM) is expressed on fetal liver HSCs, and in the AGM region on c-Kit⁺ cells and lymphoid progenitors (Yokota et al., 2009). The vast majority (>95%) of GFP/CBF β ⁺ hematopoietic and endothelial cells in the

10.5 dpc A+U+V were ESAM⁺, demonstrating that cell surface ESAM marks HSCs and HSC-producing endothelium (Figure 7A,B). However, fewer than 15% of vascular endothelial cadherin (CD144⁺) ESAM⁺ endothelial or hematopoietic cells were GFP/CBFβ⁺. Therefore ESAM cannot substitute for *Ly6a*-driven transgenes to enrich for HSCs or HSC-producing endothelium. We found the same to be true for endoglin (CD105) and Tek, i.e. most GFP/CBFβ⁺ hematopoietic or endothelial cells in the A+U+V expressed these markers, but fewer than 15% of cells expressing these markers were GFP/CBFβ⁺ (Figure 7A,C). The percentage of Flk1⁺ cells is relatively low compared to ESAM, CD105, and Tek, and less useful for isolation or analysis of HSCs and HSC-producing hemogenic endothelium (Figure 7A,C). We obtained similar results with *Ly6a-GFP* embryos (data not shown), indicating that the *Ly6a* regulatory sequences faithfully reproduce this expression pattern in independently derived transgenic mice. In summary, *Ly6a*-driven transgenes mark a subset of endothelial cells (CD31⁺, CD144⁺, ESAM⁺, CD105⁺, Tek⁺) and hematopoietic cells (c-Kit⁺ and presumably Runx1⁺) and thus enrich for HSCs and HSC-producing endothelium. *Ly6a* transgene expression does not, however, remain restricted to this small population of endothelial cells throughout development, as at later gestational ages its expression expands to other cell types including some veins, epithelial cells of the metanephric kidney, endothelial and other cells in the fetal liver, lung macrophages (Figure S4) and a variety of other adult tissues (Holmes and Stanford, 2007; Ma et al., 2002b).

Ly6a expression is not regulated by CBFβ

The restricted endothelial expression of the *Ly6a* transgene in sites of HSC emergence suggested it might be a target of Runx1-CBFβ. However, we found no evidence for this. There were GFP/CBFβ⁺ cells in the umbilical and placental vasculature in both *Ly6a-GFP/Cbfb* and *Cbfb*^{-/-}; *Ly6a-GFP/Cbfb* 11.5 dpc conceptuses, and a similar percentage of Sca1⁺ GFP/CBFβ⁺ cells in the vasculature (A+U+V, Figure S5 A,B). The percentage of GFP/CBFβ⁺ endothelial (CD45⁻CD144⁺) cells in the A+U+V was also equivalent (Figure S5 C,D), and GFP/CBFβ⁺ CD31⁺ cells were clearly visible in the endothelial layer of the dorsal aorta of 10.5 dpc *Cbfb*^{-/-}; *Ly6a-GFP/Cbfb* fetuses (Figure S5 E). Thus *Runx1* and *Ly6a* are regulated independently. Runx1 expression marks all hemogenic endothelium that gives rise to EMPs and HSCs. *Ly6a* expression, on the other hand, marks the subset of hemogenic endothelium that gives rise to HSCs (Figure 7D).

Discussion

It was previously not possible to study the genetic requirements of HSC development in the conceptus in the absence of earlier waves of EMP formation. Here we demonstrate that the formation of EMPs and HSCs can be uncoupled. The emergence of both EMPs and HSCs requires Runx1 and its non-DNA binding subunit CBFβ. EMP formation in conceptuses lacking CBFβ could be rescued by expressing a functional GFP/CBFβ fusion protein from *Tek* regulatory sequences (Miller et al., 2002). HSCs could be rescued by expressing GFP/CBFβ from *Ly6a* regulatory sequences. Thus EMPs and HSCs have different temporal and/or spatial requirements for CBFβ. *Ly6a-GFP/Cbfb* expressing endothelial cells in the yolk sac are not yet present at the time EMPs emerge, and therefore CBFβ is required before the onset of *Ly6a* expression in the yolk sac for EMP formation. On the other hand, *Ly6a-GFP/Cbfb* expression in the dorsal aorta, vitelline and umbilical vasculature precedes the emergence of HSCs, and *Ly6a-GFP/Cbfb* could rescue HSCs. That the rescue of HSCs by the *Ly6a-GFP/Cbfb* transgene was only partial could reflect a slightly earlier requirement for CBFβ in a subset of HSC precursors. Alternatively, suboptimal expression levels of *Cbfb* expression could be responsible. Previous studies showed that Runx1 haploinsufficiency differentially affected AGM HSC activity as compared to that in yolk sac and placenta, thus

suboptimal expression levels could underlie the selective failure of the *Ly6a-GFP/Cbfb* transgene to rescue aorta, vitelline and umbilical HSCs (Cai et al., 2000; Robin et al., 2006).

Activation of an inactive, floxed *Runx1* allele with *Tek-Cre* restored both EMP and HSC formation, thus the *Tek* regulatory sequences should have been expressed sufficiently early in the cells that give rise to EMPs and HSCs to rescue (Liakhovitskaia et al., 2009). The most likely reason that *Tek-GFP/Cbfb* only partially rescued EMPs, and failed to rescue HSC formation in *Cbfb*^{-/-} conceptuses is inadequate expression in endothelial cells, or in newly formed EMPs or HSCs. Partial EMP rescue by *Tek-GFP/Cbfb* could also reflect a requirement for CBF β in cells in which it is normally expressed and *Tek* is not, such as the primitive streak (Bollerot et al., 2005). *Cbfb* is expressed in the posterior aspect of the primitive streak in early and intermediate streak embryos, while *Runx1* expression initiates approximately 10 hours later in the area opaca (blood islands). Since the *Runx* proteins are reliant on CBF β for high affinity DNA binding, it would make sense for CBF β to be present before *Runx1* to ensure that, once present, *Runx1* is active. A likely explanation for the failure of *Tek-GFP/Cbfb* to rescue HSCs is that, unlike *Runx1*, sustained CBF β expression may be required in HSCs. In fact, preliminary data indicate that the number of HSCs in mice in which CBF β is deleted in the fetal liver with *Vav1-Cre* is decreased approximately 25 fold, greater than the approximate 4-fold decrease observed upon *Runx1* deletion with *Vav1-Cre* (not shown). The *Ly6a*-driven transgene, in contrast, provided sustained expression of GFP/CBF β in fetal liver HSCs. We point out that although low levels of cell surface *Tek* is present on fetal liver HSCs (Hsu et al., 2000), this does not necessarily mean that expression from a *Tek*-driven transgene would supply adequate levels of CBF β to rescue HSC formation or function.

Ly6a encodes a glycoprotein-I-linked cell-surface glycoprotein Sca1, which is a marker of stem/progenitor populations in multiple organs (Holmes and Stanford, 2007). There are two mouse strain-specific *Ly6a* alleles, only one of which is expressed in all HSCs (Spangrude and Brooks, 1993). Despite early work on *Ly6a* expression (DNaseI hypersensitivity) in the FDCP1 multipotent progenitor and other hematopoietic cell lines (Sinclair and Dzierzak, 1993), relatively little is known about the regulation of *Ly6a* expression in endothelial cells, and nothing at the transcriptional level. However, two mutant mouse models showed decreased numbers of *Ly6a-GFP* expressing aortic endothelial cells. Embryos haploinsufficient for *Gata2* (HSC numbers were reduced) showed a 10-fold decrease in GFP⁺ aortic endothelial cells (Ling et al., 2004) and conceptuses deficient for *Jagged1*, a ligand for Notch, had a 2-fold decrease (Robert-Moreno et al., 2008). *Ly6a* is regulated in HSCs by interferon α signaling through STAT1 (Essers et al., 2009), thus signaling through JAK-STAT is a possible mechanism for activating *Ly6a* expression in endothelium. We showed that *Ly6a* expression is not, however, dependent on *Runx1*-CBF β . A recent ChIP-Seq analysis of multiple transcription factors involved in hematopoietic development (*Tal1*, *Lyl1*, *Lmo2*, *Gata2*, *Runx1*, and *Pu.1*) found that the *Ly6a* gene was occupied only by *Pu.1* in a hematopoietic progenitor cell line (Wilson et al., 2010). Although EMP cell lines are fairly far removed from endothelium, the indication that *Ly6a* is not a direct *Runx1* target is consistent with our observation that *Ly6a* expression in endothelium is unaffected by CBF β deficiency. Although expression of *Ly6a* in HSCs is strain-specific, and a human equivalent does not exist, it would nevertheless be interesting to identify the signals that activate expression of the mouse transgene in the subset of endothelial cells that give rise to HSCs, as these may provide clues as to how HSCs, as opposed to EMPs, are specified. A comparison of gene expression profiles between *Ly6a-GFP*⁺ and *Ly6a-GFP*⁻ endothelium might reveal other markers that could be used to follow the development of the comparable endothelium in human embryos and ES cell cultures.

Most importantly, our data imply that there is a discrete endothelial population in the mouse conceptus that gives rise to HSCs, and the murine *Ly6a* regulatory sequences are active in these endothelial cells. Importantly, and quite unexpectedly, EMPs do not emerge if CBF β expression is restricted to *Ly6a*-expressing cells, indicating that the *Ly6a*-driven transgene is not active in the hemogenic endothelium that gives rise to EMPs at the time Runx1-CBF β is required. This interpretation is entirely consistent with known markers on EMPs and HSCs in the murine conceptus. EMPs in the yolk sac are cell surface Sca1⁻ (Huang and Auerbach, 1993), whilst HSCs in the *Ly6a-GFP* AGM region and placenta are in the GFP⁺ population (de Bruijn et al., 2002; Huang and Auerbach, 1993; Ottersbach and Dzierzak, 2005). This has important implications for ongoing efforts to produce HSCs *ex vivo*, from ES/induced pluripotent stem cells and fibroblasts. Many investigators have generated EMPs and lymphoid progenitors from these cell sources, but no functional HSCs have been produced without introducing genetic modifications (Cho et al., 1999; Irion et al., 2010; Lengerke and Daley, 2010; Schmitt et al., 2004; Szabo et al., 2010). EMP formation proceeds through an endothelial intermediate in ES cell cultures (Eilken et al., 2009; Lanclin et al., 2009), and presumably HSC formation will as well. It would therefore be useful to follow the generation of *Ly6a-GFP*⁺ endothelial cells *in vitro* when optimizing conditions for HSC production.

Materials and Methods

Generation of *Ly6a-GFP/Cbfb* transgenes

We generated *Ly6a-GFP/Cbfb* mice by inserting a cDNA coding for a GFP/CBF β fusion protein into the *Ly6a* promoter/enhancer sequences. We introduced silent mutations into the cDNA for GFP/CBF β (Adja et al., 1998) (a gift from Paul Liu) to eliminate the *SalI*, *XhoI*, *BglII*, *XhoI*, and *HindIII* sites in order to facilitate cloning. An artificial intron and poly-A signal was added to the 3' end of the coding region. The GFP/CBF β insert was amplified by PCR to introduce *Clal* sites at both ends then inserted into the *Clal* site of pPOLYIII-Ly6A14 (Ma et al., 2002a). The insert was flanked by 4 kb of upstream and 10 kb of downstream genomic sequences containing *Ly6a* regulatory elements. The transgene was excised from the vector by *BamHI* and injected into fertilized oocytes from C57BL/6 \times 129S1/SVImJ F1 mice by the Brigham and Women's transgenic facility. Six independent founders were identified, and three further characterized. *Tek-GFP/Cbfb* and *Cbfb*^{+/-} (*Cbfb*^{tm1Spe/+}) mice were described previously (Miller et al., 2002; Wang et al., 1996b).

PCR genotyping protocol and primers

Animals were genotyped by PCR using tail DNA from adults, and yolk sac snips or limb buds from conceptuses. The *Tek-GFP/Cbfb* transgene was detected by the following primers: Tek-PF263: 5' AGC GGG AAG TCG CAA AGT TGT G, GFP-R138: 5' CTT CAG GGT CAG CTT GCC GTA G. The *Ly6a-GFP/Cbfb* transgene was detected by: Ly6A-PF55: 5' AGA ACT TGC CAC TGT GCC TGC and GFP-R138: 5' CTT CAG GGT CAG CTT GCC GTA G. *Cbfb*^{+/-} was detected by three primers: CBFbex5R: 5' CTC TCA CCT CCA TTT CCT CCC G. CBFbex5F: 5' TAT TTC ATG TAC CCT GAC AGC AGG. PGKP-R-475: 5' ATG CTC CAG ACT GCC TTG GG. The *Cbfb* deleted allele yields a ~400 bp band, and the wild type *Cbfb* allele yields a ~110 bp band. All PCR reactions were run using the following program: 5 min denaturation at 94°C followed by 35 cycles of denaturation (30 sec at 94°C), annealing (30 sec at 60°C), and elongation (1 min 30 sec at 72°C).

Embryo and mouse generation

Conceptuses were generated from timed matings. Detection of the vaginal plug is 0.5 dpc. *Ly6a-GFP/Cbfb* and *Cbfb*^{+/-}; *Ly6a-GFP/Cbfb* conceptuses were generated by crossing

Cbfb^{+/-}; *Tg* males with *Cbfb*^{+/-} females. The same strategy was used to generate *Cbfb*^{-/-}; *Tek-GFP/Cbfb* conceptuses.

Cell Preparation

Embryonic cells were prepared for flow cytometry, methylcellulose and transplant assays as described previously (Chen et al., 2009; North et al., 2002).

Flow cytometry

We used PerCP-Cy5.5 anti-Sca-1 (D7), eFluor® 450 lineage specific cocktail [(anti-TER119 (TER119), anti-Gr-1 (RB6-8C5), anti-B220 (RA3-6B2), anti-CD3 (17A2), anti-Mac-1 (M1/70)], APC anti-CD48 (HM48-1), APC- eFluor® 780 anti-c-Kit (2B8) (eBioscience), and PE-Cy7 anti-CD150 (SLAM) (BioLegend) to stain adult bone marrow. Fetal liver cell staining is as above except for removal of eFluor® 450 anti-Mac-1 from the lineage cocktail, and staining with PE anti-Mac-1 (M1/70). Dead cells were excluded with DAPI (Molecular Probes). To analyze peripheral blood engraftment we used PerCP-Cy5.5 anti-Gr-1 (RB6-8C5), APC anti-CD3e (145-2C11), PE anti-CD19 (1D3), PE-Cy7 anti-Mac-1 (M1/70) (BD Pharmingen), V450 anti-CD45.2 (104) (BD Horizon), and PE-Cy5 anti-CD45.1 (A20). Dead cells were excluded with Fixable Viability Dye eFluor® 780 (eBioscience). To examine HSC/endothelial marker expression we used PE-Cy7-anti-CD31 (390), Alexafluor® 647-anti-CD144 (eBioBV13), PE-anti-CD105 (MJ7/18), PE-anti-Tie2 (TEK4) (eBioscience); PE-anti-ESAM (1G8/ESAM) and PE-anti-Flk1 (89B3A5) (BioLegend). Dead cells were excluded by DAPI staining. We analyzed cells on an LSR II flow cytometer (BD Biosciences, San Jose CA), and data by FlowJo (Tree Star, Ashland, OR). Cells were sorted on a FACSaria (BD Biosciences).

Cell culture

OP9 and OP9-DL4 cells were essentially used as described (Schmitt and Zuniga-Pflucker, 2006). For OP9-DL4 cultures, IL-7 was added at a final concentration of 1 ng/ml and Flt3 ligand at 5 ng/ml. OP9 cultures included IL-7 at a final concentration of 10 ng/ml. Stromal cells were plated 2 days before initiation of culture at a concentration of 20,000 cells/ml in 96-well plates. Cultures were examined after 7 days of culture by flow cytometry. For *in vitro* limiting-dilution analysis, the progenitor frequency was calculated using the method of maximum likelihood applied to Poisson distribution with L-Calc software (StemCell Technologies).

Transplant analyses

129S1/SvImJ × B6.SJL-*Ptprca*^a *Pepc*^b/BoyJ F1 mice (CD45.1/CD45.2) were subjected to a split dose of 900 cGy, 3 hours apart. Each recipient received 0.9 embryo equivalent of donor fetal liver, yolk sac, placenta, or AGM and arteries, and 2 × 10⁵ carrier spleen cells via tail vein injection. All donor fetuses were of a mixed C57BL/6J and 129S1/SVImJ background and expressed CD45.2. Spleen cells were prepared from B6.SJL-*Ptprca*^a *Pepc*^b/BoyJ (CD45.1) mice. We assessed donor engraftment of peripheral blood 16 weeks later.

Western-blot analyses

Bone marrow was isolated and resuspended at 1 × 10⁶ cells per ml in lysis buffer (150 mM NaCl, 50 mM Tris, pH8.0, 1% Nonidet P-40, 0.5% deoxycholate, 0.1% SDS, 0.2 mM EDTA, 2.0 mM EGTA plus 1 µg/ml pepstatin A, 1 µM Pefablock, 2 µg/ml leupeptin, 2 µg/ml aprotinin). Lysates equivalent to 2 × 10⁵ cells were boiled in SDS loading buffer, resolved by SDS-PAGE through 4–12% Bis-Tris gels (Invitrogen), proteins transferred to nitrocellulose, the blot probed with mouse monoclonal antibodies to CBFβ (β141.4.1 + β141.2.2.5), and developed with ECL reagents (Pico kit, Pierce, Rockford, IL).

Microscopy and Imaging

Images of dissected intact conceptuses in phosphate-buffered saline were visualized using a Leica MZFIII stereomicroscope equipped with a Plan 1X 0.14(.025–.125) objective lens (Leica, Heerbrugg, Switzerland). A Color Mosaic 11.2 camera and Spot Insight 4.0 acquisition software (Diagnostic Instruments, Sterling Heights, MI) were used to capture images, which were processed with Adobe Photoshop CS4 software (Adobe Systems, San Jose, CA).

Whole mount immunohistochemistry was performed as described (Yokomizo and Dzierzak, 2010; Yokomizo et al., 2011). Biotinylated rat anti-mouse CD31 (MEC13.3, BD Biosciences) and rabbit anti-GFP polyclonal antibody (MBL, Naka-ku Nagoya) were used with Cy-3-conjugated streptavidin (Jackson Immuno Research, West Grove PA) and Alexafluor® 647 goat anti-rabbit IgG (Invitrogen). Specimens were analyzed with a Leica DM 6000 upright confocal microscope with HCX PL FLUOTAR 5.0 × 0.15, NA 0.15/ HCX PL APO CS 10.0 × 0.4, NA 0.4 objectives using multi-track sequential mode. Pinhole diameter was set at 1 Airy unit and steps were 1.3–9.7µm per z-section.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The authors thank Tomomasa Yokomizo for teaching us how to perform the whole mount immunohistochemistry. We are especially grateful to Andrea Stout for her help with confocal microscopy. This work was supported by R01HL091724 (NAS) and Netherlands Institute of Regenerative Medicine (ED). Core services were supported by the Abramson Family Cancer Research Institute and the Abramson Cancer Center.

References

- Adja N, Stacy T, Speck NA, Liu PP. The leukemic protein CBFβ-SMMHC sequesters CBFα2 into cytoskeletal filaments and aggregates. *Mol Cell Biol.* 1998; 18:7432–7443. [PubMed: 9819429]
- Bertrand JY, Chi NC, Santoso B, Teng S, Stainier DY, Traver D. Haematopoietic stem cells derive directly from aortic endothelium during development. *Nature.* 464:108–111. [PubMed: 20154733]
- Boisset JC, van Cappellen W, Andrieu-Soler C, Galjart N, Dzierzak E, Robin C. In vivo imaging of haematopoietic cells emerging from the mouse aortic endothelium. *Nature.* 2010; 464:116–120. [PubMed: 20154729]
- Bollerot K, Romero S, Dunon D, Jaffredo T. Core binding factor in the early avian embryo: cloning of Cbfbeta and combinatorial expression patterns with Runx1. *Gene Expr Patterns.* 2005; 6:29–39. [PubMed: 16033710]
- Cai Z, de Bruijn MFTR, Ma X, Dortland B, Luteijn T, Downing JR, Dzierzak E. Haploinsufficiency of AML1/CBFA2 affects the embryonic generation of mouse hematopoietic stem cells. *Immunity.* 2000; 13:423–431. [PubMed: 11070161]
- Chen MJ, Yokomizo T, Zeigler BM, Dzierzak E, Speck NA. Runx1 is required for the endothelial to haematopoietic cell transition but not thereafter. *Nature.* 2009; 457:889–891.
- Cho SK, Webber TD, Carlyle JR, Nakano T, Lewis SM, Zuniga-Pflucker JC. Functional characterization of B lymphocytes generated in vitro from embryonic stem cells. *Proc Natl Acad Sci U S A.* 1999; 96:9797–9802. [PubMed: 10449774]
- de Bruijn M, Ma X, Robin C, Ottersbach K, Sanchez M-J, Dzierzak E. Hematopoietic stem cells localize to the endothelial cell layer in the midgestation mouse aorta. *Immunity.* 2002; 16:673–683. [PubMed: 12049719]
- de Bruijn MF, Speck NA, Peeters MC, Dzierzak E. Definitive hematopoietic stem cells first develop within the major arterial regions of the mouse embryo. *EMBO J.* 2000; 19:2465–2474. [PubMed: 10835345]

- Eilken HM, Nishikawa S, Schroeder T. Continuous single-cell imaging of blood generation from haemogenic endothelium. *Nature*. 2009; 457:896–900. [PubMed: 19212410]
- Essers MA, Offner S, Blanco-Bose WE, Waibler Z, Kalinke U, Duchosal MA, Trumpp A. IFN α activates dormant haematopoietic stem cells in vivo. *Nature*. 2009; 458:904–908. [PubMed: 19212321]
- Ferkowicz MJ, Starr M, Xie X, Li W, Johnson SA, Shelley WC, Morrison PR, Yoder MC. CD41 expression defines the onset of primitive and definitive hematopoiesis in the murine embryo. *Development*. 2003; 130:4393–4403. [PubMed: 12900455]
- Gekas C, Dieterlen-Lievre F, Orkin SH, Mikkola HK. The placenta is a niche for hematopoietic stem cells. *Dev Cell*. 2005; 8:365–375. [PubMed: 15737932]
- Holmes C, Stanford WL. Concise review: stem cell antigen-1: expression, function, and enigma. *Stem Cells*. 2007; 25:1339–1347. [PubMed: 17379763]
- Hsu HC, Ema H, Osawa M, Nakamura Y, Suda T, Nakauchi H. Hematopoietic stem cells express Tie-2 receptor in the murine fetal liver. *Blood*. 2000; 96:3757–3762. [PubMed: 11090057]
- Huang H, Auerbach R. Identification and characterization of hematopoietic stem cells from the yolk sac of the early mouse embryo. *Proc Natl Acad Sci U S A*. 1993; 90:10110–10114. [PubMed: 8234265]
- Irion S, Clarke RL, Luche H, Kim I, Morrison SJ, Fehling HJ, Keller GM. Temporal specification of blood progenitors from mouse embryonic stem cells and induced pluripotent stem cells. *Development*. 2010; 137:2829–2839. [PubMed: 20659975]
- Jaffredo T, Nottingham W, Liddiard K, Bollerot K, Pouget C, de Bruijn M. From hemangioblast to hematopoietic stem cell: an endothelial connection? *Exp Hematol*. 2005; 33:1029–1040. [PubMed: 16140151]
- Kissa K, Herbomel P. Blood stem cells emerge from aortic endothelium by a novel type of cell transition. *Nature*. 2010; 464:112–115. [PubMed: 20154732]
- Kissa K, Murayama E, Zapata A, Cortes A, Perret E, Machu C, Herbomel P. Live imaging of emerging hematopoietic stem cells and early thymus colonization. *Blood*. 2008; 111:1147–1156. [PubMed: 17934068]
- Lancrin C, Sroczynska P, Stephenson C, Allen T, Kouskoff V, Lacaud G. The haemangioblast generates haematopoietic cells through a haemogenic endothelium stage. *Nature*. 2009; 457:892–895. [PubMed: 19182774]
- Lengerke C, Daley GQ. Autologous blood cell therapies from pluripotent stem cells. *Blood Rev*. 2010; 24:27–37. [PubMed: 19910091]
- Li Z, Chen MJ, Stacy T, Speck NA. Runx1 function in hematopoiesis is required in cells that express Tek. *Blood*. 2006; 107:106–110. [PubMed: 16174759]
- Liakhovitskaia A, Gribi R, Stamateris E, Villain G, Jaffredo T, Wilkie R, Gilchrist D, Yang J, Ure J, Medvinsky A. Restoration of Runx1 expression in the Tie2 cell compartment rescues definitive hematopoietic stem cells and extends life of Runx1 knockout animals until birth. *Stem Cells*. 2009; 27:1616–1624. [PubMed: 19544462]
- Ling KW, Ottersbach K, van Hamburg JP, Oziemlak A, Tsai FY, Orkin SH, Ploemacher R, Hendriks RW, Dzierzak E. GATA-2 plays two functionally distinct roles during the ontogeny of hematopoietic stem cells. *J Exp Med*. 2004; 200:871–882. [PubMed: 15466621]
- Ma X, de Bruijn M, Robin C, Peeters M, Kong-A-San J, Snoija C, Dzierzak E. Expression of the Ly-6A (Sca-1) lacZ transgene in mouse hematopoietic stem cells and embryos. *Br J Haematol*. 2002a; 116:401–408. [PubMed: 11841445]
- Ma X, Robin C, Ottersbach K, Dzierzak E. The Ly-6A (Sca-1) GFP transgene is expressed in all adult mouse hematopoietic stem cells. *Stem Cells*. 2002b; 20:514–521. [PubMed: 12456959]
- Medvinsky A, Dzierzak E. Definitive hematopoiesis is autonomously initiated by the AGM region. *Cell*. 1996; 86:897–906. [PubMed: 8808625]
- Medvinsky AL, Gan OI, Semenova ML, Samoylina NL. Development of day-8 colony-forming unit-spleen hematopoietic progenitors during early embryogenesis: spatial and temporal mapping. *Blood*. 1996; 87:557–566. [PubMed: 8555477]

- Miller J, Horner A, Stacy T, Lowrey C, Lian JB, Stein G, Nuckolls GH, Speck NA. The core-binding factor β subunit is required for bone formation and hematopoietic maturation. *Nat Genet.* 2002; 32:645–649. [PubMed: 12434155]
- Müller AM, Medvinsky A, Strouboulis J, Grosveld F, Dzierzak E. Development of hematopoietic stem cell activity in the mouse embryo. *Immunity.* 1994; 1:291–301. [PubMed: 7889417]
- North TE, de Bruijn MF, Stacy T, Talebian L, Lind E, Robin C, Binder M, Dzierzak E, Speck NA. Runx1 expression marks long-term repopulating hematopoietic stem cells in the midgestation mouse embryo. *Immunity.* 2002; 16:661–672. [PubMed: 12049718]
- North TE, Gu T-L, Stacy T, Wang Q, Howard L, Binder M, Marín-Padilla M, Speck NA. *Cbfa2* is required for the formation of intra-aortic hematopoietic clusters. *Development.* 1999; 126:2563–2575. [PubMed: 10226014]
- Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. *Cell.* 1996; 84:321–330. [PubMed: 8565077]
- Ottersbach K, Dzierzak E. The murine placenta contains hematopoietic stem cells within the vascular labyrinth region. *Dev Cell.* 2005; 8:377–387. [PubMed: 15737933]
- Palis J, Robertson S, Kennedy M, Wall C, Keller G. Development of erythroid and myeloid progenitors in the yolk sac and embryo proper of the mouse. *Development.* 1999; 126:5073–5084. [PubMed: 10529424]
- Robert-Moreno A, Guiu J, Ruiz-Herguido C, Lopez ME, Ingles-Esteve J, Riera L, Tipping A, Enver T, Dzierzak E, Gridley T, et al. Impaired embryonic haematopoiesis yet normal arterial development in the absence of the Notch ligand Jagged1. *Embo J.* 2008; 27:1886–1895. [PubMed: 18528438]
- Robin C, Ottersbach K, Durand C, Peeters M, Vanes L, Tybulewicz V, Dzierzak E. An unexpected role for IL-3 in the embryonic development of hematopoietic stem cells. *Dev Cell.* 2006; 11:171–180. [PubMed: 16890157]
- Sasaki K, Yagi H, Bronson RT, Tominaga K, Matsunashi T, Deguchi K, Tani Y, Kishimoto T, Komori T. Absence of fetal liver hematopoiesis in mice deficient in transcriptional coactivator core binding factor beta. *Proc Natl Acad Sci USA.* 1996; 93:12359–12363. [PubMed: 8901586]
- Schmitt TM, de Pooter RF, Gronski MA, Cho SK, Ohashi PS, Zuniga-Pflucker JC. Induction of T cell development and establishment of T cell competence from embryonic stem cells differentiated in vitro. *Nat Immunol.* 2004; 5:410–417. [PubMed: 15034575]
- Schmitt TM, Zuniga-Pflucker JC. T-cell development, doing it in a dish. *Immunol Rev.* 2006; 209:95–102. [PubMed: 16448536]
- Sinclair AM, Dzierzak EA. Cloning of the complete Ly-6E.1 gene and identification of DNase I hypersensitive sites corresponding to expression in hematopoietic cells. *Blood.* 1993; 82:3052–3062. [PubMed: 8219196]
- Spangrude GJ, Brooks DM. Mouse strain variability in the expression of the hematopoietic stem cell antigen Ly-6A/E by bone marrow cells. *Blood.* 1993; 82:3327–3332. [PubMed: 8241503]
- Szabo E, Rampalli S, Risueno RM, Schnerch A, Mitchell R, Fiebig-Comyn A, Levadoux-Martin M, Bhatia M. Direct conversion of human fibroblasts to multilineage blood progenitors. *Nature.* 2010
- Talebian L, Li Z, Guo Y, Gaudet J, Speck ME, Sugiyama D, Kaur P, Pear WS, Maillard I, Speck NA. T lymphoid, megakaryocyte, and granulocyte development are sensitive to decreases in CBF β dosage. *Blood.* 2007; 109:11–21. [PubMed: 16940420]
- Wang Q, Stacy T, Binder M, Marín-Padilla M, Sharpe AH, Speck NA. Disruption of the *Cbfa2* gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. *Proc Natl Acad Sci USA.* 1996a; 93:3444–3449. [PubMed: 8622955]
- Wang Q, Stacy T, Miller JD, Lewis AF, Huang X, Bories J-C, Bushweller JH, Alt FW, Binder M, Marín-Padilla M, et al. The CBF β subunit is essential for CBF α (AML1) function in vivo. *Cell.* 1996b; 87:697–708. [PubMed: 8929538]
- Wilson NK, Foster SD, Wang X, Knezevic K, Schutte J, Kaimakis P, Chilarska PM, Kinston S, Ouwehand WH, Dzierzak E, et al. Combinatorial transcriptional control in blood stem/progenitor cells: genome-wide analysis of ten major transcriptional regulators. *Cell Stem Cell.* 2010; 7:532–544. [PubMed: 20887958]

- Yan J, Liu Y, Lukasik SM, Speck NA, Bushweller JH. CBFbeta allosterically regulates the Runx1 Runt domain via a dynamic conformational equilibrium. *Nat Struct Mol Biol.* 2004; 11:901–906. [PubMed: 15322525]
- Yoder MC, Hiatt K, Mukherjee P. In vivo repopulating hematopoietic stem cells are present in the murine yolk sac at day 9.0 postcoitus. *Proc Natl Acad Sci U S A.* 1997; 94:6776–6780. [PubMed: 9192641]
- Yokomizo T, Dzierzak E. Three-dimensional cartography of hematopoietic clusters in the vasculature of whole mouse embryos. *Development.* 2010; 137:3651–3661. [PubMed: 20876651]
- Yokomizo T, Yamada-Inagawa T, Yzaguirre AD, Chen MJ, Speck NA, Dzierzak E. Whole mount 3-dimensional imaging of internally-localized immunostained cells within mouse embryos. *Nat Protocols.* 2011 *in press.*
- Yokota T, Oritani K, Butz S, Kokame K, Kincade PW, Miyata T, Vestweber D, Kanakura Y. The endothelial antigen ESAM marks primitive hematopoietic progenitors throughout life in mice. *Blood.* 2009; 113:2914–2923. [PubMed: 19096010]
- Zovein AC, Hofmann JJ, Lynch M, French WJ, Turlo KA, Yang Y, Becker MS, Zanetta L, Dejana E, Gasson JC, et al. Fate tracing reveals the endothelial origin of hematopoietic stem cells. *Cell Stem Cell.* 2008; 3:625–636. [PubMed: 19041779]




Figure 1. Expression of GFP/Cbfb from the Tek regulatory sequences poorly rescues lymphoid progenitor and HSC formation

A. Fetal liver progenitors ($\text{Lin}^- \text{Kit}^+ \text{Flt3}^+$) were sorted from 14.5 dpc embryos and plated on OP9 or OP9-DL4 stromal cells. Number of cells plated were 400 and 200 *Tek-GFP/Cbfb* on OP9 and OP9-DL4, respectively; 2000 *Cbfb*^{-/-}; *Tek-GFP/Cbfb* on both OP9 and OP9-DL4. OP9 cultures contained 5 ng/ml Flt3L, 10ng/ml IL7. OP9-DL4 cultures contained 5 ng/ml Flt3L, 1 ng/ml IL7. Cells were analyzed for the expression of lymphoid markers 7 days later.

B. Limit dilution analysis of fetal liver progenitors cultured as described above.

C. Percent and number of recipients containing 5% donor-derived blood 16 weeks following transplantation with 2×10^5 , 5×10^5 , or 1×10^6 14.5 dpc fetal liver cells from wild type (+/+), *Cbfb*^{-/-} (-/-), and *Cbfb*^{-/-}; *Tek-GFP/Cbfb* (-/-; Tek) conceptuses.

D. Representative scatter plots of 13.5 dpc fetal liver HSCs (LSK cells).

E. Total number of fetal liver and LSK cells at 13.5 dpc. Data are compiled from 2–5 fetuses. Error bars represent standard error of the mean (SEM).

F. Representative histograms showing GFP/CBF β expression in the LSK and LT-HSC populations of 13.5 dpc *Tek-GFP/Cbfb* fetal livers. The two green traces and percentages in the histograms represent two independent fetuses.




Figure 2. Expression of GFP/CBF β in endothelial cells and hematopoietic cells from the *Ly6a-GFP/Cbfb* transgene

A. Western blot analysis of whole bone marrow from wild type, *Ly6a-GFP*, and three independent *Ly6a-GFP/Cbfb* lines using a monoclonal antibody recognizing CBF β . Endogenous CBF β and the GFP/CBF β fusion protein are indicated. Whole cell lysates from 2×10^5 cells were loaded.

B. Representative histograms showing GFP/CBF β expression in the LSK and LT-HSC populations in the bone marrow (BM) of three independent lines of adult *Ly6a-GFP/Cbfb* mice.

C. (Left) Whole mount immunofluorescence of an 11.5 dpc *Ly6a-GFP/Cbfb* conceptus. The fetus is outlined with a dashed white line. PI, placenta; UA, umbilical artery. (Right) An isolated AGM region with expression in the dorsal aorta (DA), vitelline artery (VA), UA, mesonephric tubules (MT), and Wolffian/Mullerian ducts (W/M), identical to that reported for the *Ly6a-GFP* transgene (de Bruijn et al., 2002).

D. Representative histograms showing GFP/CBF β expression in the majority phenotypic LT-HSC in a 13.5 dpc *Ly6a-GFP/Cbfb* fetal liver (FL, Line A).




Figure 3. EMPs in $Cbfb^{-/-}$ conceptuses are rescued upon expression of GFP/CBF β from the Tek but not the Ly6a-driven transgene. See also Figure S1

Shown are the numbers of hematopoietic progenitors (colonies) per embryo equivalent (ee) in four hematopoietic tissues: fetal liver, yolk sac, AGM region combined with umbilical and vitelline arteries (A+U+V), and placenta. Numbers are compiled from 3–14 11.5 or 14.5 dpc conceptuses per genotype. P values in boxes indicate significant differences in total progenitor numbers in $Cbfb^{-/-}$ conceptuses (-/-, indicated by #) versus $Cbfb^{-/-}$ conceptuses carrying transgenes as determined by one-way ANOVA. Error bars represent SEM.

Asterisks indicate significant differences compared to -/- ($P < 0.01$) according to Dunnett's Multiple Comparison test. Differences between $Cbfb^{-/-}$, $Cbfb^{-/-}; Tek-GFP/Cbfb$ (-/-; Tek) and $Cbfb^{-/-}; Ly6a-GFP/Cbfb$ (-/-; Ly6a) were determined by unpaired two-tailed Student's t test. $Cbfb^{-/-}; Tek-GFP/Cbfb; Ly6a-GFP/Cbfb$ is -/-; Tek+Ly6a.




Figure 4. Expression of GFP/CBF β from the Ly6a regulatory sequences rescues HSCs in Cbfb^{-/-} conceptuses

A. Repopulation by 0.9 ee of 11.5 dpc cells from conceptuses of the indicated genotypes at 4 months post transplant. Percent engraftment represents the percent donor-derived blood; each dot is an individual transplant recipient. Error bars represent SEM.

B. Multi-lineage engraftment by donor derived wild type and Cbfb^{-/-}; Ly6a-GFP/Cbfb HSCs in a recipient of placenta cells.




Figure 5. Expression of the Tek-GFP/Cbfb and Ly6a-GFP/Cbfb transgenes in 8.5–9.5 dpc conceptuses analyzed by confocal microscopy. See also Figure S2 and Movie S2

A. Whole mount immunofluorescence of a 7s *Tek-GFP/Cbfb* conceptus using antibodies recognizing CD31 and GFP (10X). Scale bars for all panels = 100 μ m. Figure represents the MAX of six consecutive 3 μ m z-sections for CD31 and GFP. DA, dorsal aorta; YS, yolk sac; AI, allantois; PI, placenta; H, heart.

B. A 11s *Ly6a-GFP/Cbfb* conceptus, analyzed as described in A.

C. A 16s *Tek-GFP/Cbfb* conceptus reconstructed as the standard deviation (STD) of 13 consecutive 1.3 μ m z-sections for CD31, and the SUM for GFP (10X).

D. A 16s *Ly6a-GFP/Cfb* conceptus, analyzed as described in C. Expression is observed in endothelial cells in the caudal aspect of the dorsal aortae, placenta, yolk sac (primarily caudal region), vitelline artery (VA), vitelline vein (VV), foregut (Fg), and in the hindgut (not shown). See also Movie S1.




Figure 6. Expression of the Tek-GFP/Cbfb and Ly6a-GFP/Cbfb transgenes in 10.5 dpc conceptuses. See also Figures S3, S5

A. Whole mount immunofluorescence of a 36s *Tek-GFP/Cbfb* specimen using antibodies recognizing CD31 and GFP (5X). Scale bars = 100 μ m. View represents AVG of fourteen 10 μ m z-sections. DA, dorsal aorta; UA, umbilical artery; VA, vitelline artery, FI, fetal liver.

B. A 38s *Ly6a-GFP/Cbfb* specimen, analyzed as described in A. The *Ly6a-GFP/Cbfb* transgene is also highly expressed in the tail. MT, Mullerian tubules; HG, hindgut. See also Movie S3.

C. Yolk sac from the *Tek-GFP/Cbfb* fetus shown in A (5X). View represents SUM of 32 9.7 μ m z-sections. Asterisk shows area of expression in the yolk sac vascular plexus.

- D. Yolk sac from the *Ly6a-GFP/Cbfb* fetus shown in B, analyzed as described in C. Arrows show expression in large vitelline vessels.
- E. Umbilical artery from the *Tek-GFP/Cbfb* fetus shown in A (20X). View represents SUM of six 0.38 μ m z-sections.
- F. Umbilical artery from the *Ly6a-GFP/Cbfb* fetus shown in B (20X), analyzed as described in E.
- G. Intra-arterial hematopoietic cluster from the umbilical artery of a *Tek-GFP/Cbfb* fetus (20X).
- H. Intra-arterial hematopoietic cluster from the umbilical artery of a *Ly6a-GFP/Cbfb* fetus, as in G.




Figure 7. Ly6a transgene expression marks a subset of CD144⁺, ESAM⁺, CD105⁺, Tek⁺, Flk1⁺, and c-Kit⁺ cells. See also Figure S4

A. Live (DAPI negative) cells from the 10.5 dpc A+U+V were gated for GFP/CBF β in the plot furthest to the left, and GFP/CBF β ⁺ cells are shown as red dots in this and all other plots.

B. Live cells are gated for CD31 and c-Kit expression and divided into endothelial cells (CD31⁺ c-Kit⁻) and hematopoietic cells (CD31⁺ c-Kit⁺). Each population in turn is analyzed for ESAM and CD144 expression, and all ESAM⁺ cells for CD144 and GFP/CBF β expression. Black numbers represent the percentage of all cells in a particular gate, while red numbers represent percentages of GFP/CBF β ⁺ cells in that gate.

- C. Analysis of CD105⁺, Tek⁺, and Flk1⁺ populations, gated as described in A,B.
- D. Diagram illustrating that Ly6a-GFP expression marks the HSC-producing population of Runx1⁺ hemogenic endothelium.